Krystal Biotech (KRYS) Depreciation & Amortization (CF) (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Depreciation & Amortization (CF) data on file, last reported at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 7.94% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $5.7 million (down 2.64% YoY), and the FY2025 full-year result was $5.7 million, down 4.47% from the prior year.
• Depreciation & Amortization (CF) rose to $1.5 million in Q1 2026, from $1.5 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.8 million in Q2 2024 to a low of $705000.0 in Q1 2023.
• A 5-year average of $1.2 million and a median of $1.3 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) plunged 30.54% in 2023 and jumped 98.58% in 2024, its largest moves.
• Tracing KRYS's Depreciation & Amortization (CF) over 5 years: stood at $1.1 million in 2022, then jumped by 39.94% to $1.5 million in 2023, then fell by 10.3% to $1.4 million in 2024, then climbed by 9.73% to $1.5 million in 2025, then advanced by 1.47% to $1.5 million in 2026.
• Business Quant data shows KRYS's Depreciation & Amortization (CF) at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $1.4 million in Q3 2025.